Abstract:
본 발명은 기계적 강도, 전기적 특성 또는 산소·수증기 차단 특성이 향상된 고분자 복합재료를 제조하기 위하여 탄소재료를 환원 및 기능화하는 단계 및 상기 환원 및 기능화된 탄소재료를 고분자 전구체 중합 과정에 첨가하고 반응시켜 고분자 복합재료를 제조하는 단계를 포함하여 구성되는 환원 및 기능화된 그래핀 옥사이드를 포함하는 고분자 복합재료 및 그 제조방법에 관한 것이다.
Abstract:
The present invention relates to a polymer-based large-area carbon nanomesh and a manufacturing method thereof and, more specifically, to a manufacturing method for a carbon nanomesh, comprising: a polymer nanofilm manufacturing step of manufacturing a polymer nanofilm by coating a substrate with block copolymers or mixed polymer solutions including at least two kinds of polymer solutions; a stabilization step of separating the polymer nanofilm by heat-treating the manufactured polymer nanofilm and allowing nanomesh forming polymers to form porous polymer nanomeshes by induced thermal stabilization while pore forming polymers are removed; and a carbonization step of manufacturing a carbon nanomesh by carbonizing the stabilized porous polymer nanomesh through a high temperature thermal treatment. Accordingly, the present invention provides the polymer-based large-area carbon nanomesh which is suitable for mass production since a process exhibits high reproducibility even through the process is simple by using cyclization reaction and phase separation properties of polymers and has excellent activity of a large area, and to the manufacturing method thereof.
Abstract:
본 발명에 따르면 폴리아크릴로나이트릴계 고분자 및 그래핀 산화물을 포함하는 전기 전도성 복합재료용 조성물, 및 상기 조성물을 사용하여 보다 단순화된 방법으로 전기 전도성이 우수한 복합재료를 제조할 수 있는 방법이 제공된다. 본 발명에 따르면, 탄소계 소재의 분산성을 향상시키기 위한 별도의 전처리 과정을 요구되지 않으며, 저렴한 가격의 탄소계 소재의 전구체를 이용할 수 있어 경제적으로 유리할 뿐만 아니라, PAN계 고분자 전구체의 안정화 및 낮은 온도에서의 탄화 과정에서 전기 전도도를 갖는 복합재료를 단순화된 방법으로 제조할 수 있다.
Abstract:
PURPOSE: A carbon material using metal-polymer composites and a method for manufacturing the same are provided to adjust the thickness of the carbon material through a non-melting process and to improve the quality of the carbon material. CONSTITUTION: One or more metal components are selected from metals or metal precursors. A metal-polymer composite layer including the metal components and a polymer is formed. The metal-polymer composite layer is infusibilized in order to suppress the decomposition of the polymer contained in the metal-polymer composite layer during a carbonating process. The metal-polymer composite layer is carbonated. The infusibilization process is selected one or more selected from an alkali-based treating process, a thermal treating process under inert gas or vacuum atmosphere, and a physical treating process based on plasma, ion beam, radioactive ray, ultraviolet ray, and microwaves.
Abstract:
PURPOSE: A composition containing naringin or naringenin for inhibition of the platelet coagulation is provided, which prevents coagulation of platelets caused by exposed collagen when blood vessel endothelial cells is damaged; so which can prevents and cures formation of atheroma, or thrombosis; and which can be used in a medicine and food. CONSTITUTION: A naringin or naringenin is extracted from oranges(a grapefruit, a citron, a lemon, a orange, etc) or manufactured from well-known synthetic process. A pharmaceutical composition as an inhibitor to platelet coagulation comprises of naringin or naringenin as an effective ingredient and pharmaceutically acceptable carriers, which can also contains diluents, disintegrators, sweeteners, lubricants, perfume; and which can be made in the form of tablets, capsules, powders, suspensions, emulsions, syrup, solution or parenteral preparations. A dosage of the composition for inhibition of the platelet coagulation containing naringin or naringenin is 0.5-100mg/kg, desirably 2-10mg/kg. The naringin or naringenin can be added in food or beverages with same purposes.
Abstract:
PURPOSE: A composition is provided to help to improve the blood flow by preventing a platelet cohesion and a formation of a thrombus at the same time. CONSTITUTION: The hesperidins or the hesperetin is effective to prevent and treat the sclerosis of the arteries by the platelet cohesion, and to improve of the blood flow by preventing the platelet cohesion generated by collagen. The composition for the platelet cohesion prevention is able to prescribe as a non-oral administration or to prescribe as an oral administration, and to prescribe the hesperidins or the hesperetin 0.5 mg or 100 mg for 1 kg per a day.